Abstract
The glyoxalase enzymes represent a cellular defence system against the accumulation of cytotoxic α- oxoaldehydes leading to apoptosis. The potential of glyoxalase inhibitors to act as novel anti-cancer agents for drugresistant tumours that over-express glyoxalase is currently under investigation. In the present study, a series of 6- sulfamoylsaccharin and 1,2-benzoxathiine 2,2-dioxide (sulfocoumarin - coumarin bioisostere) derivates, as well as, transcinnamic acid (the mimic of coumarin hydrolysis product) have been tested for the inhibition of glyoxalase 1 and 2. For the first time, it has been demonstrated, that 6-sulfamoylsaccharin possesses glyoxalase 1 inhibitory activity (IC50=90±15 μM). Two compounds, 5b and 9c, slightly inhibited the activity of glyoxalase 2. In addition, it has been demonstrated that trans-cinnamic acid inhibits glyoxalase 1 activity (IC50=84±4 μM). These data indicate that the modification of 6- sulfamoylsaccharin structure and coumarin hydrolysis products can be used to develop potential glyoxalase 1 inhibitors.
Keywords: 1, 2-benzoxathiine 2, 2-dioxide, Glyoxalase 1, Glyoxalase 2, 6-sulfamoylsaccharin, Sulfocoumarin, Trans-cinnamic acid
Letters in Drug Design & Discovery
Title:Glyoxalase 1 and 2 Enzyme Inhibitory Activity of 6-Sulfamoylsaccharin and Sulfocoumarin Derivates
Volume: 10 Issue: 5
Author(s): Marina Makrecka, Raivis Zalubovskis, Edijs Vavers, Jekaterina Ivanova, Aiga Grandane and Maija Dambrova
Affiliation:
Keywords: 1, 2-benzoxathiine 2, 2-dioxide, Glyoxalase 1, Glyoxalase 2, 6-sulfamoylsaccharin, Sulfocoumarin, Trans-cinnamic acid
Abstract: The glyoxalase enzymes represent a cellular defence system against the accumulation of cytotoxic α- oxoaldehydes leading to apoptosis. The potential of glyoxalase inhibitors to act as novel anti-cancer agents for drugresistant tumours that over-express glyoxalase is currently under investigation. In the present study, a series of 6- sulfamoylsaccharin and 1,2-benzoxathiine 2,2-dioxide (sulfocoumarin - coumarin bioisostere) derivates, as well as, transcinnamic acid (the mimic of coumarin hydrolysis product) have been tested for the inhibition of glyoxalase 1 and 2. For the first time, it has been demonstrated, that 6-sulfamoylsaccharin possesses glyoxalase 1 inhibitory activity (IC50=90±15 μM). Two compounds, 5b and 9c, slightly inhibited the activity of glyoxalase 2. In addition, it has been demonstrated that trans-cinnamic acid inhibits glyoxalase 1 activity (IC50=84±4 μM). These data indicate that the modification of 6- sulfamoylsaccharin structure and coumarin hydrolysis products can be used to develop potential glyoxalase 1 inhibitors.
Export Options
About this article
Cite this article as:
Makrecka Marina, Zalubovskis Raivis, Vavers Edijs, Ivanova Jekaterina, Grandane Aiga and Dambrova Maija, Glyoxalase 1 and 2 Enzyme Inhibitory Activity of 6-Sulfamoylsaccharin and Sulfocoumarin Derivates, Letters in Drug Design & Discovery 2013; 10 (5) . https://dx.doi.org/10.2174/1570180811310050007
DOI https://dx.doi.org/10.2174/1570180811310050007 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting of NF-kappaB Signaling Pathway, other Signaling Pathways and Epigenetics in Therapy of Multiple Myeloma
Cardiovascular & Hematological Disorders-Drug Targets Annexins in the Central Nervous System: Are they Neuroprotective or Proapoptotic Agents?
Medicinal Chemistry Reviews - Online (Discontinued) Current Status of Leukemia Cytotherapy - Exploitation with Immune Cells
Current Stem Cell Research & Therapy In Situ Gene Therapy for Prostate Cancer
Current Gene Therapy FAK and Nanog Cross Talk with p53 in Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment
Current Topics in Medicinal Chemistry Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Bacteriocins Active Against Multi-Resistant Gram Negative Bacteria Implicated in Nosocomial Infections
Infectious Disorders - Drug Targets Recent Advances in the Therapeutic Perspectives of Nutlin-3
Current Pharmaceutical Design New and Highly Potent Antitumor Natural Products from Marine-Derived Fungi: Covering the Period from 2003 to 2012
Current Topics in Medicinal Chemistry Emerging Molecular Functions of MicroRNA-9: Cancer Pathology and Therapeutic Implications
Anti-Cancer Agents in Medicinal Chemistry Microenvironmental Regulation of Cancer Stem Cell Phenotypes
Current Stem Cell Research & Therapy The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases
Current Molecular Pharmacology Human Mesenchymal Stem Cells (hMSCs) as Targets of DNA Damaging Agents in Cancer Therapy
Current Cancer Drug Targets New Developments in Targeted Analysis of Protein Posttranslational Modifications
Current Proteomics Targeting the mTOR Pathway in Tumor Malignancy
Current Cancer Drug Targets Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
Current Genomics A Review on CRISPR-mediated Epigenome Editing: A Future Directive for Therapeutic Management of Cancer
Current Drug Targets Human Sirtuins: An Overview of an Emerging Drug Target in Age-Related Diseases and Cancer
Current Drug Targets The Review of the Synthesis of Bestatin, an Effective Inhibitor of Aminopeptidase N
Mini-Reviews in Organic Chemistry